A Phase 1 interventional study of BIA 9-1067 and Placebo in Parkinson Disease, sponsored by Bial - Portela C S.A.. Completed at 1 site in Canada. Open to participants aged 25 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-16.
Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing opicapone in Parkinson Disease — none open to participants now, none under way, none of them phase 3. opicapone · Parkinson Disease.
Among the 38 studies testing opicapone in Parkinson Disease, this one is the 15th largest by enrollment, is one of 10 that started in 2009, is one of 27 in phase 1, and was the 16th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 38 studies testing opicapone in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
opicapone: first FDA approval 2020 (ONGENTYS), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 25 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 28 across the 38 interventional studies. Of the 38 that completed or were terminated, 24 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 38 have an industry lead sponsor. The 6 most frequent:
Bial - Portela C S.A. is the lead sponsor of 136 studies on the registry; 1 is open to participants now.
60 studies in Parkinson Disease by Bial - Portela C S.A.: 1 open now, 2 under way, none of them phase 3. Of 57 finished, 27 (47%) have results posted.
Among the 60 studies in Parkinson Disease by Bial - Portela C S.A., this one is the 18th largest by enrollment of the 56 interventional ones that give a count, is one of 10 that started in 2009, is one of 45 in phase 1, and was the 16th registered.
Bial - Portela C S.A.’s Parkinson Disease studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing opicapone in Parkinson Disease, from their registry updates:
Among Bial - Portela C S.A.’s 60 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics
Single centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4 groups of healthy subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
Drug: BIA 9-1067 · Drug: levodopa/carbidopa · Drug: levodopa/benserazide
Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
Drug: Placebo · Drug: levodopa/carbidopa · Drug: levodopa/benserazide
15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
Drug: BIA 9-1067 · Drug: levodopa/carbidopa · Drug: levodopa/benserazide
30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
Drug: BIA 9-1067 · Drug: levodopa/carbidopa · Drug: levodopa/benserazide
Also known as: OPC, Opicapone
Also known as: PLC, Placebo
Drug pages: Levodopa · Carbidopa
Also known as: Sinemet® 100/25
Also known as: Prolopa® 100/25
Cmax - Maximum Plasma Concentration
Cmax - maximum plasma concentration Cmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®
Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
Tmax - Time to Maximum Plasma Concentration
Tmax - time to maximum plasma concentration Tmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®
Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point
AUC0-t - area under the plasma concentration-time curve from time 0 to last observed concentration 3-OMD - 3-O-methyl-dopa - metabolite of L-DOPA (levodopa) AUC0-t (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®
Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity
tEmax - time of occurrence of maximum observed effect on S-COMT activity COMT - Catechol-O-Methyltransferase
Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose
AUEC0-24 - Area under the effect-time curve (AUEC) to 24 h post-dose.
Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
| Milestone | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 |
|---|---|---|---|---|
| Started | 14 | 13 | 13 | 12 |
| Completed | 12 | 12 | 12 | 12 |
| Not completed | 2 | 1 | 1 | 0 |
Cmax - maximum plasma concentration Cmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®
| ng/mL | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 |
|---|---|---|---|---|
| Cmax (Levodopa) Sinemet® 100/25 | 985 ± 290 | 1245 ± 524 | 1200 ± 607 | 944 ± 256 |
| Cmax (Levodopa) Prolopa® 100-25 | 1704 ± 682 | 2100 ± 907 | 1727 ± 957 | 1795 ± 788 |
| Cmax (3-OMD) Sinemet® 100/25 | 456 ± 130 | 307 ± 106 | 167 ± 82.5 | 115 ± 54.5 |
| Cmax (3-OMD) Prolopa® 100/25 | 688 ± 230 | 360 ± 96 | 206 ± 110.8 | 160 ± 61.9 |
| Cmax (BIA 9-1067) Sinemet® 100/25 | NA ± NA | 75.0 ± 39 | 263 ± 82.3 | 310 ± 115 |
| Cmax (BIA 9-1067) Prolopa® 100/25 | NA ± NA | 95.5 ± 41.1 | 281 ± 153.4 | 370 ± 181.7 |
Tmax - time to maximum plasma concentration Tmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®
| hours | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 |
|---|---|---|---|---|
| Tmax (Levodopa) Sinemet® 100/25 | 0.5 (0.5 to 3.0) | 0.75 (0.5 to 3.0) | 0.5 (0.5 to 1.5) | 1.0 (0.5 to 2.0) |
| Tmax (Levodopa) Prolopa® 100-25 | 1.0 (0.5 to 2.0) | 1.0 (0.5 to 1.5) | 1.0 (0.5 to 2.0) | 1.0 (0.5 to 2.0) |
| Tmax (3-OMD) Sinemet® 100/25 | 4.0 (4.0 to 6.0) | 8.0 (6.0 to 8.0) | 6.0 (3.0 to 8.0) | 8.0 (4.0 to 8.0) |
| Tmax (3-OMD) Prolopa® 100/25 | 4.0 (3.0 to 6.0) | 8.0 (4.0 to 8.0) | 6.0 (2.0 to 8.0) | 4.0 (3.0 to 8.0) |
| Tmax (BIA 9-1067) Sinemet® 100/25 | NA (NA to NA) | 1.5 (0.5 to 6.0) | 3.0 (1.5 to 6.0) | 4.0 (1.5 to 6.0) |
| Tmax (BIA 9-1067) Prolopa® 100/25 | NA (NA to NA) | 3.0 (1.0 to 4.0) | 2.5 (0.5 to 6.0) | 3.0 (1.0 to 6.0) |
AUC0-t - area under the plasma concentration-time curve from time 0 to last observed concentration 3-OMD - 3-O-methyl-dopa - metabolite of L-DOPA (levodopa) AUC0-t (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®
| ng.h/mL | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 |
|---|---|---|---|---|
| AUC0-t (Levodopa) Sinemet® 100/25 | 1837 ± 593 | 3386 ± 1449 | 2952 ± 1003 | 2753 ± 889 |
| AUC0-t (Levodopa) Prolopa® 100-25 | 2438 ± 712 | 4115 ± 1547 | 3442 ± 1225 | 4056 ± 1051 |
| AUC0-t (3-OMD) Sinemet® 100/25 | 7631 ± 1786 | 5147 ± 1534 | 2836 ± 1495 | 1751 ± 988 |
| AUC0-t (3-OMD) Prolopa® 100/25 | 11371 ± 3707 | 6205 ± 1458 | 3473 ± 1962 | 2623 ± 1065 |
| AUC0-t (BIA 9-1067) Sinemet® 100/25 | NA ± NA | 223 ± 58.2 | 872 ± 412 | 1101 ± 525 |
| AUC0-t (BIA 9-1067) Prolopa® 100/25 | NA ± NA | 232 ± 82.4 | 836 ± 497 | 1185 ± 562 |
tEmax - time of occurrence of maximum observed effect on S-COMT activity COMT - Catechol-O-Methyltransferase
| hours | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 |
|---|---|---|---|---|
| tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity | 8.12 ± 8.15 | 2.71 ± 2.16 | 4.67 ± 1.92 | 3.50 ± 2.41 |
AUEC0-24 - Area under the effect-time curve (AUEC) to 24 h post-dose.
| pmol/mg Hb/h.h | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 |
|---|---|---|---|---|
| AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose | 906 ± 276 | 454 ± 97.3 | 319 ± 134 | 226 ± 177 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/14 (0%) | 11/14 (78.6%) |
| 5 mg BIA 9-1067 | — | 0/13 (0%) | 9/13 (69.2%) |
| 15 mg BIA 9-1067 | — | 0/13 (0%) | 11/13 (84.6%) |
| 30 mg BIA 9-1067 | — | 0/12 (0%) | 9/12 (75%) |
| Event | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 |
|---|---|---|---|---|
| SomnolenceNervous system disorders | 5/14 | 3/13 | 5/13 | 6/12 |
| HeadacheNervous system disorders | 2/14 | 1/13 | 1/13 | 3/12 |
| DizzinessNervous system disorders | 2/14 | 3/13 | 1/13 | 1/12 |
| Disturbance in attentionNervous system disorders | 0/14 | 0/13 | 0/13 | 2/12 |
| Ocular hyperaemiaEye disorders | 1/14 | 1/13 | 2/13 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/14 | 2/13 | 0/13 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 2/14 | 2/13 | 2/13 | 1/12 |
| FatigueGeneral disorders | 1/14 | 0/13 | 2/13 | 1/12 |
| RashSkin and subcutaneous tissue disorders | 1/14 | 0/13 | 2/13 | 1/12 |
| NauseaGastrointestinal disorders | 2/14 | 1/13 | 1/13 | 1/12 |
| Age, Categorical(Participants) | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 13 | 13 | 12 | 52 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | 5 mg BIA 9-1067 | 15 mg BIA 9-1067 | 30 mg BIA 9-1067 | Total |
|---|---|---|---|---|---|
| Female | 7 | 6 | 6 | 6 | 25 |
| Male | 7 | 7 | 7 | 6 | 27 |
The record gives a start of Mar 2009, a primary completion of Aug 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Opicapone · Levodopa · Carbidopa